Mentor Capital, Inc. - Investor's Corner (Contract)

Mentor Capital, Inc. and CI Companies

$10M Cancer Assets
3M Basic Shares

About Mentor Capital About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance Investor's Corner (Contract) Analysts' Coverage $5/Share - Sr. Securities Analyst Cancer Imm Index Information Visit Portfolio Companies

Trading Chart

Investor's Corner

All PDF Documents will open a new browser window

Standard Cancer Equity Funding Contract
All PDF Documents will open a new browser window Cancer Company $10,000,000 Long-Term Equity Funding Example

Warrant Description
All PDF Documents will open a new browser window $125 Million in Proceeds from MNTR Warrants

2011 Q3 Financials
All PDF Documents will open a new browser window Mentor Capital Financials – 2011 3 Quarters

2010 Annual FInancials
All PDF Documents will open a new browser window Mentor Capital, December 31, 2010

2009 Annual FInancials
All PDF Documents will open a new browser window Mentor Capital, December 31, 2009

2008 Audited Financials
All PDF Documents will open a new browser window Mentor Capital, Inc. Audited Financial Statements - December 31, 2008 and 2007

15(c) 2-11
All PDF Documents will open a new browser window Mentor Capital Inc. Disclosure Statement Pursuant To Rule 15(c) 2-11

Historic Registration/Section 1145 Document (January 11, 2000)
All PDF Documents will open a new browser window Tradability, Warrant Redemptions, Non-Dilution of Warrants on Reverse Split, Compensation

The Mentor Capital Cancer Immunotherapy Index ^©

For Email Marketing you can trust

See Actual Cancer
Vaccine Results!

Home

Changing Assets & Acquisitions

Warrant Information

Chairman's Letters

◦	Bringing It All Together To Win In The Cancer Fight (2011)
◦	Welcome To The Team Leading The Cancer Fight (2010)

Medicine, Science & The Economy

◦	Sunlight Explains Japan Radiation Risk

Press Releases

◦	Mentor Capital Acquires 50 Percent of Brighter Day Health For $5M
◦	Mentor Capital Begins its 2012 Cancer Roll-up Strategy
◦	MNTR acquires 30 Percent of European Cancer Vaccine for $4.71 Million
◦	Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine
◦	Mentor Capital Reports Mid-Year Profits for 2011
◦	Mentor Capital Initiates Discussions for Potential Merger
◦	Mentor Capital Seeks Funding Partners as Neutron Cancer Therapy Accelerates
◦	Cancer Immunotherapy Index Outpaces Biotechs
◦	Increased Chinese and International Visitors to Mentor Capital Site
◦	CEO Purchases an Additional 3.14% of MNTR Shares
◦	MNTR Drafts Five Cancer Funding Contracts for $40 Million
◦	MNTR Screens Cancer Companies For Investment At ASCO
◦	MNTR Acquires $5M Hadron Neutron Therapy Interest
◦	$125 Million for Socially Responsible Direct Cancer Funding
◦	Advaxis Added To Cancer Immunotherapy Index
◦	MNTR In Discussion With Breast Cancer Immunotherapy Company
◦	Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science
◦	Mentor Capital to Expand Funding Bridge Over Cancer Development Gap
◦	Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	MNTR Presents in NYC
◦	QI Announces MNTR
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

Safe Harbor Statement Site Map